Table 1.

Pharmacokinetic analysis of a single subcutaneous dose of short-acting lanreotide and lanreotide Autogel^® in healthy subjects

	Short-acting lanreotidea n = 24	lanreotide Autogela n = 24	lanreotide Autogelb n = 10	lanreotide Autogelb n = 10
Dose	7 μg/kg	60 mg	90 mg	120 mg
Cmax	7.98 ng/mL	5.71 ng/mL	6.7 ng/mL
Tmax	0.43 h	0.38 day	2.4 day	1.1 day
Half-life	1.74 h	22 days	25.5 day
AUC	16.51 ng.mL−1.h	79.48 ng.mL−1.day	116 ng.mL−1.day	133 ng.mL−1.day
MRT	1.95 h	31.97 days

^aAntonijoan et al (2004);

^bAstruc et al (2005).

Abbreviations: AUC, area under the curve; MRT, mean residence time.